Clinical Trial Search

Primary: The Absolute Change From Baseline in the Inflammatory Lesion Count at Week 12. — 16.39; 12.74 Lesion Count

Primary: Number of Participants With Treatment Emergent Adverse Events (AEs), Treatment Emergent Serious Adverse Events (SAEs), Treatment Related AEs and Treatment Related SAEs…

Primary: Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Concentration (AUC0-tz) — 5990…

Primary: Safety Outcome Measure — 185; 207; 155 AEs

Primary: Percentage of Participants Who Experienced an HES Flare or Who Withdrew From the Study During the 32-Week Study Treatment Period — 56; 28 Percentage of participants…

Primary: Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) for Empagliflozin — 5656.07…

Primary: Response Rate (RR) — 19 Participants

Primary: Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days (MHD) — -3.60; -3.36; -0.59 Days — p=<0.001

Primary: Change From Baseline in Average Low Back Pain Intensity (LBPI) Score for Tanezumab Versus (Vs) Placebo at Week 16 — -2.68; -2.98; -3.08; -2.81 units on a scale — p=0.1117

Primary: Number of Participants With Preterm Birth — 24; 20 Participants

Primary: Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (SAEs) and Any Treatment-Emergent Adverse Events (AEs). — 0.0; 16.7; 0.0; 0.0…

Primary: Efficiency of Propofol Dexmedetomidine Sedation Compared With Propofol Infusion — 98; 77 minutes

Primary: Multiple Dose: Area Under the Concentration Time Curve From 0 to 24 Hours (AUC0-24) of Talazoparib — 94.88; 106.5; 135.7; 249.8 nanogram*hour per milliliter

Primary: Percentage of Cocaine-positive Urines — 67.6; 69 percentage of cocaine-positive urines

Primary: Postoperative Pain — 3.2; 3; 3.9 Score on scale 0-10